Filing Flows › Insulet (PODD) › How it makes money
How Insulet (PODD) makes money
Insulet (PODD) made $842M of revenue in the third quarter 2026 (Q3 2026), +19% from a year earlier. Total Omnipod products brought in $837M (99%); Drug Delivery brought in $5.5M (1%). Of every dollar of revenue, 75¢ was left as gross profit, 23¢ was left as operating profit, 17¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Total Omnipod products | $837M | 99.3% | +5% | +20% |
| ↳ U.S. | $570M | 67.7% | +5% | +15% |
| ↳ International | $266M | 31.6% | +6% | +32% |
| Drug Delivery | $5.5M | 0.7% | -5% | -23% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $842M | 100.0% |
| Cost of revenue | $210M | 24.9% |
| Gross profit | $632M | 75.1% |
| Operating expenses | $442M | 52.5% |
| Operating profit | $190M | 22.5% |
| Income tax | $36.1M | 4.3% |
| Net earnings | $141M | 16.8% |
| Operating cash flow | $124M | 14.7% |
| Free cash flow | $66.4M | 7.9% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $842M | +19% |
| Q2 2026 | $802M | +24% |
| Q1 2026 | $762M | +34% |
| Q4 2025 | $784M | +31% |
| Q3 2025 | $706M | +30% |
| Q2 2025 | $649M | +33% |
| Q1 2025 | $569M | +29% |
From Insulet's 10-Q filed Nov 4, 2026 (on EDGAR).
Questions
How does Insulet make money?
Insulet (PODD) made $842M of revenue in the third quarter 2026 (Q3 2026), +19% from a year earlier. Total Omnipod products brought in $837M (99%); Drug Delivery brought in $5.5M (1%). Of every dollar of revenue, 75¢ was left as gross profit, 23¢ was left as operating profit, 17¢ was left as net earnings.
What is Insulet's biggest business?
Total Omnipod products: $837M in the third quarter 2026, 99% of revenue, +20% from a year earlier.
What is Insulet's profit margin?
Net earnings were $141M, 16.8% of revenue, in the third quarter 2026; the operating margin was 22.5%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.